[go: up one dir, main page]

PL2056874T3 - Leczenie nowotworu przeciwciałem przeciw VEGF - Google Patents

Leczenie nowotworu przeciwciałem przeciw VEGF

Info

Publication number
PL2056874T3
PL2056874T3 PL07786693T PL07786693T PL2056874T3 PL 2056874 T3 PL2056874 T3 PL 2056874T3 PL 07786693 T PL07786693 T PL 07786693T PL 07786693 T PL07786693 T PL 07786693T PL 2056874 T3 PL2056874 T3 PL 2056874T3
Authority
PL
Poland
Prior art keywords
vegf antibody
tumor therapy
tumor
therapy
vegf
Prior art date
Application number
PL07786693T
Other languages
English (en)
Inventor
Thomas Friess
Max Hasmann
Werner Scheuer
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37607207&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2056874(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PL2056874T3 publication Critical patent/PL2056874T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
PL07786693T 2006-08-21 2007-08-17 Leczenie nowotworu przeciwciałem przeciw VEGF PL2056874T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP06017330 2006-08-21
PCT/EP2007/007276 WO2008022746A1 (en) 2006-08-21 2007-08-17 Tumor therapy with an anti-vegf antibody
EP07786693A EP2056874B1 (en) 2006-08-21 2007-08-17 Tumor therapy with an anti-vegf antibody

Publications (1)

Publication Number Publication Date
PL2056874T3 true PL2056874T3 (pl) 2013-02-28

Family

ID=37607207

Family Applications (1)

Application Number Title Priority Date Filing Date
PL07786693T PL2056874T3 (pl) 2006-08-21 2007-08-17 Leczenie nowotworu przeciwciałem przeciw VEGF

Country Status (28)

Country Link
US (6) US20080050385A1 (pl)
EP (2) EP2441472B1 (pl)
JP (3) JP2010501498A (pl)
KR (1) KR101136763B1 (pl)
CN (1) CN101505792B (pl)
AR (1) AR062419A1 (pl)
AU (1) AU2007287794B2 (pl)
BR (1) BRPI0715829A2 (pl)
CA (1) CA2660681A1 (pl)
CL (1) CL2007002404A1 (pl)
CO (1) CO6150193A2 (pl)
CR (1) CR10590A (pl)
DK (1) DK2056874T3 (pl)
ES (2) ES2546066T3 (pl)
IL (2) IL196810A0 (pl)
MA (1) MA30654B1 (pl)
MX (1) MX2009001715A (pl)
MY (1) MY150756A (pl)
NO (1) NO20090450L (pl)
NZ (1) NZ574580A (pl)
PE (1) PE20080911A1 (pl)
PL (1) PL2056874T3 (pl)
RU (1) RU2528884C2 (pl)
SG (1) SG174090A1 (pl)
SI (1) SI2056874T1 (pl)
TW (2) TW201107346A (pl)
WO (1) WO2008022746A1 (pl)
ZA (1) ZA200901200B (pl)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL152656A0 (en) 2000-05-19 2003-06-24 Genentech Inc Gene detection assay for improving the likelihood of an effective response to an erbb antagonist cancer therapy
AU2005287404B2 (en) * 2004-07-22 2009-05-07 Genentech, Inc. HER2 antibody composition
JO3000B1 (ar) * 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
AU2005314127A1 (en) * 2004-12-07 2006-06-15 Genentech, Inc. Selecting patients for therapy with a HER inhibitor
MX2007008768A (es) 2005-01-21 2007-10-19 Genentech Inc Dosificacion fija de anticuerpos her.
CN103251946A (zh) 2005-02-23 2013-08-21 健泰科生物技术公司 使用her二聚化抑制剂在癌症患者中延长病情进展前时间或存活
PE20070207A1 (es) * 2005-07-22 2007-03-09 Genentech Inc Tratamiento combinado de los tumores que expresan el her
MY150756A (en) * 2006-08-21 2014-02-28 Hoffmann La Roche Tumor theraphy with an anti-vegf antibody
PE20090681A1 (es) 2007-03-02 2009-06-10 Genentech Inc Prediccion de respuesta a un inhibidor her
TWI472339B (zh) 2008-01-30 2015-02-11 Genentech Inc 包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物
BRPI0812682A2 (pt) 2008-06-16 2010-06-22 Genentech Inc tratamento de cáncer de mama metastático
CA3051311A1 (en) 2010-05-27 2011-12-01 Genmab A/S Monoclonal antibodies against her2
EP2575880B1 (en) 2010-05-27 2019-01-16 Genmab A/S Monoclonal antibodies against her2 epitope
CN103140761B (zh) * 2010-07-19 2015-11-25 霍夫曼-拉罗奇有限公司 贝伐单抗组合疗法用于治疗胰腺癌的血浆生物标志物
PL2606070T3 (pl) * 2010-08-20 2017-06-30 Novartis Ag Przeciwciała dla receptora epidermalnego czynnika wzrostu 3 (her3)
JP2014514314A (ja) 2011-04-20 2014-06-19 ゲンマブ エー／エス Ｈｅｒ２およびｃｄ３に対する二重特異性抗体
DK4403228T3 (da) 2011-10-14 2025-10-13 Hoffmann La Roche Anvendelser for og fremstillet artikel indbefattende HER2-dimeriseringshæmmeren pertuzumab
AR089067A1 (es) * 2011-12-05 2014-07-30 Hoffmann La Roche Biomarcadores en el plasma sanguineo para terapias de combinacion de bevacizumab destinadas al tratamiento del cancer de mama
WO2013148159A1 (en) * 2012-03-30 2013-10-03 Fibrogen Inc Therapeutic methods for peritoneal carcinomatosis
RU2737727C2 (ru) 2013-04-16 2020-12-02 Дженентек, Инк. Варианты пертузумаба и их аналитическая характеристика
RU2020120593A (ru) 2014-04-25 2020-09-01 Дженентек, Инк. Способы лечения раннего рака молочной железы трастузумабом-mcc-dm1 и пертузумабом
TW201619200A (zh) * 2014-10-10 2016-06-01 麥迪紐有限責任公司 人類化抗－ｏｘ４０抗體及其用途
ES2984592T3 (es) 2015-05-30 2024-10-30 Hoffmann La Roche Procedimientos de tratamiento de cáncer de mama metastásico no tratado previamente positivo para HER2
WO2017087280A1 (en) 2015-11-16 2017-05-26 Genentech, Inc. Methods of treating her2-positive cancer
CN106729743B (zh) * 2015-11-23 2021-09-21 四川科伦博泰生物医药股份有限公司 抗ErbB2抗体-药物偶联物及其组合物、制备方法和应用
TW202140776A (zh) * 2016-04-26 2021-11-01 美商美國泰福生技股份有限公司 細胞培養基
AU2017387909A1 (en) 2016-12-28 2019-06-27 Genentech, Inc. Treatment of advanced HER2 expressing cancer
TW202508629A (zh) 2017-01-17 2025-03-01 美商建南德克公司 皮下her2抗體調配物
KR20230144110A (ko) 2017-03-02 2023-10-13 제넨테크, 인크. Her2-양성 유방암 어쥬번트 치료
KR20190140952A (ko) 2017-04-24 2019-12-20 제넨테크, 인크. 막관통 및 인접막 도메인에서의 erbb2/her2 돌연변이
JP2023532122A (ja) 2020-06-29 2023-07-26 ジェネンテック， インコーポレイテッド ペルツズマブにトラスツズマブを加えた固定用量配合剤
JP2023541141A (ja) * 2020-09-04 2023-09-28 ザ ボード オブ スーパーバイザーズ オブ ルイジアナ ステート ユニバーシティ アンド アグリカルチュラル アンド メカニカル カレッジ がんを治療するための組み合わせ組成物及び方法

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3040121B2 (ja) 1988-01-12 2000-05-08 ジェネンテク，インコーポレイテッド 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
EP1238986B1 (en) 1992-10-28 2008-06-25 Genentech, Inc. Use of Vascular endothelial cell growth factor antagonists
CA2259222A1 (en) 1996-06-27 1997-12-31 Pfizer Inc. Derivatives of 2-(2-oxo-ethylidene)-imidazolidin-4-one and their use as farnesyl protein transferase inhibitors
JP2001504326A (ja) 1996-10-18 2001-04-03 ジェネンテック インコーポレーテッド 抗ＥｒｂＢ２抗体
US20020032315A1 (en) 1997-08-06 2002-03-14 Manuel Baca Anti-vegf antibodies
US6884879B1 (en) * 1997-04-07 2005-04-26 Genentech, Inc. Anti-VEGF antibodies
ES2236634T3 (es) 1997-04-07 2005-07-16 Genentech, Inc. Anticuerpos anti-vegf.
EP2338915A3 (en) 1997-04-07 2011-10-12 Genentech, Inc. Anti-VEGF antibodies
ZA9811162B (en) 1997-12-12 2000-06-07 Genentech Inc Treatment with anti-ERBB2 antibodies.
JPH11236333A (ja) 1997-12-30 1999-08-31 Pfizer Prod Inc 抗ガン剤として有用なイミダゾリン−４−オン誘導体
BR9910511A (pt) 1998-05-15 2001-11-20 Imclone Systems Inc Tratamento de tumores humanos com radiação einibidores de tirosina cinases receptoras de fatorde crescimento
CA2341690C (en) 1998-08-27 2007-04-17 Pfizer Products Inc. Alkynyl-substituted quinolin-2-one derivatives useful as anticancer agents
BR9913315A (pt) 1998-08-27 2001-05-22 Pfizer Prod Inc Derivados de quinolin-2-ona úteis como agentes anticâncer
JP2002530081A (ja) 1998-11-18 2002-09-17 ジェネンテック・インコーポレーテッド 親抗体より高度な結合親和性を持つ抗体変異体
EP1006113A1 (en) 1998-12-02 2000-06-07 Pfizer Products Inc. Derivatives of 2-(2-oxo-ethylidene)-imidazolidin-4-one and their use to inhibit abnormal cell growth
WO2000035956A1 (fr) 1998-12-16 2000-06-22 Kyowa Hakko Kogyo Co., Ltd. Anticorps monoclonal anti-vegf humain
ID29584A (id) 1999-02-11 2001-09-06 Pfizer Prod Inc Turunan-turunan kuinolin-2-on tersubstitusi heteroaril yang bermanfaat sebagai zat-zat anti kanker
US6586447B1 (en) 1999-04-01 2003-07-01 Pfizer Inc 3,3-disubstituted-oxindole derivatives useful as anticancer agents
EP1187632B1 (en) 1999-05-14 2008-12-03 Genentech, Inc. TREATMENT WITH ANTI-ErbB2 ANTIBODIES
GEP20104998B (en) 1999-06-25 2010-06-10 Genentech Inc Humanized antibody which binds erbb2 and blocks activation by ligand receptor of erbb2 (variants) and use of the composition comprising these antibodies methods for treating cancer
US6949245B1 (en) * 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
CA2383493C (en) 1999-06-25 2010-08-10 Genentech, Inc. Treating prostate cancer with anti-erbb2 antibodies
ES2212971T3 (es) 1999-11-30 2004-08-16 Pfizer Products Inc. Derivados de quinolina utiles para la inhibicion de la farnesil protein transferasa.
UA75055C2 (uk) 1999-11-30 2006-03-15 Пфайзер Продактс Інк. Похідні бензоімідазолу, що використовуються як антипроліферативний засіб, фармацевтична композиція на їх основі
HN2000000266A (es) 2000-01-21 2001-05-21 Pfizer Prod Inc Compuesto anticanceroso y metodo de separacion de enantiomeros util para sintetizar dicho compuesto.
CA2466279A1 (en) * 2001-11-13 2003-05-22 Dana-Farber Cancer Institute, Inc. Agents that modulate immune cell activation and methods of use thereof
AU2003222252A1 (en) 2002-03-12 2003-09-29 The General Hospital Corporation Use of signal transduction inhibitors and combination therapies for the prevention or treatment of cancer and angiogenesis related diseases
ES2401428T3 (es) 2002-04-10 2013-04-19 Genentech, Inc. Variantes de anticuerpos anti-HER2
WO2005000090A2 (en) 2003-05-30 2005-01-06 Medi-Screw, Inc. Medical implant systems
RS20150135A1 (sr) 2003-05-30 2015-08-31 Genentech Inc. Tretman sa anti-vegf antitelima
EP1664115A2 (en) 2003-08-01 2006-06-07 Genentech, Inc. Antibody cdr polypeptide sequences with restricted diversity
US20050106667A1 (en) * 2003-08-01 2005-05-19 Genentech, Inc Binding polypeptides with restricted diversity sequences
WO2005063816A2 (en) 2003-12-19 2005-07-14 Genentech, Inc. Monovalent antibody fragments useful as therapeutics
CA2577082A1 (en) * 2004-09-02 2006-03-16 Genentech, Inc. Heteromultimeric molecules
AU2005294146B2 (en) * 2004-10-04 2011-09-15 Genentech, Inc. Modulators of hepatocyte growth factor activator
EP3130350A1 (en) * 2005-06-08 2017-02-15 Dana-Farber Cancer Institute, Inc. Methods and compositions for the treatment of persistent infections and cancer by inhibiting the programmed cell death 1 (pd-1)pathway
TW200812615A (en) * 2006-03-22 2008-03-16 Hoffmann La Roche Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2
MY150756A (en) * 2006-08-21 2014-02-28 Hoffmann La Roche Tumor theraphy with an anti-vegf antibody
JP2013103182A (ja) * 2011-11-15 2013-05-30 Toray Ind Inc スパイラル型流体分離素子およびその製造方法

Also Published As

Publication number Publication date
US20100285010A1 (en) 2010-11-11
MY150756A (en) 2014-02-28
JP2013163687A (ja) 2013-08-22
NO20090450L (no) 2009-02-27
JP2015214582A (ja) 2015-12-03
DK2056874T3 (da) 2012-10-15
CR10590A (es) 2009-03-20
KR20090032136A (ko) 2009-03-31
JP2010501498A (ja) 2010-01-21
US20180251536A1 (en) 2018-09-06
RU2528884C2 (ru) 2014-09-20
TW201107346A (en) 2011-03-01
AU2007287794A1 (en) 2008-02-28
IL196810A0 (en) 2011-08-01
US20110223159A1 (en) 2011-09-15
EP2056874B1 (en) 2012-09-19
KR101136763B1 (ko) 2012-04-24
PE20080911A1 (es) 2008-08-15
CL2007002404A1 (es) 2008-04-18
US20150239969A1 (en) 2015-08-27
ES2546066T3 (es) 2015-09-18
NZ574580A (en) 2011-12-22
WO2008022746A1 (en) 2008-02-28
SG174090A1 (en) 2011-09-29
MA30654B1 (fr) 2009-08-03
SI2056874T1 (sl) 2012-12-31
ZA200901200B (en) 2013-08-28
EP2441472A1 (en) 2012-04-18
BRPI0715829A2 (pt) 2013-07-23
CA2660681A1 (en) 2008-02-28
TW200825106A (en) 2008-06-16
EP2441472B1 (en) 2015-06-10
AU2007287794B2 (en) 2013-03-28
EP2056874A1 (en) 2009-05-13
RU2009110102A (ru) 2010-09-27
CN101505792A (zh) 2009-08-12
HK1134441A1 (en) 2010-04-30
CN101505792B (zh) 2012-10-03
MX2009001715A (es) 2009-02-25
AR062419A1 (es) 2008-11-05
CO6150193A2 (es) 2010-04-20
US20080050385A1 (en) 2008-02-28
IL238045A0 (en) 2015-05-31
ES2392630T3 (es) 2012-12-12
US20130183292A1 (en) 2013-07-18

Similar Documents

Publication Publication Date Title
IL238045A0 (en) Tumor treatment with an antibody against vegf
IL205547A0 (en) Anti-vegf antibody compounds and methods
IL229512A (en) Anti-vegf antibodies
ZA200906345B (en) Anti-sclerostin antibodies
SI2195026T1 (sl) Protitelesa proti sklerostinu
PT2242773T (pt) Anticorpos monoclonais para o tratamento de tumores
IL243376A0 (en) Antagonistic antibody against epha2 for cancer treatment
IL186662A0 (en) Combination cancer therapy with
IL179891A0 (en) Tumor specific antibody
ZA201104110B (en) Antibodies that specifically block the biological activity of a tumor antigen
EP2331134A4 (en) ANTI-PANCREAS CANCER ANTIBODY
IL196960A0 (en) Anti-c5ar antibodies with improved properties
IL186980A0 (en) Characterizing prostate cancer
GB0815788D0 (en) Therapeutic antibodies
IL198354A0 (en) Genetic variations associated with tumors
EP1841467A4 (en) COMBINATION CANCER THERAPY WITH ANTI-PSMA ANTIBODIES
EP2324059A4 (en) THERAPEUTIC ANTI-PAMP ANTIBODIES
IL210247A0 (en) Ccl20 - specific antibodies for cancer therapy
AU2006905191A0 (en) Antibody therapy
HK1157353A (en) Anti-pamp therapeutic antibodies
AU2006905591A0 (en) Tumour selective antibody
IL207478A0 (en) Monoclonal antibodies for tumor treatment
GB0612259D0 (en) Cancer therapeutic
GB0606702D0 (en) Cancer therapeutic
GB0604689D0 (en) The cure for cancer